[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.149.128. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Case Report/Case Series
October 2015

Nephrogenic Systemic Fibrosis Manifesting a Decade After Exposure to Gadolinium

Author Affiliations
  • 1Department of Dermatology, University of Virginia School of Medicine, Charlottesville
  • 2Department of Dermatopathology, University of Virginia School of Medicine, Charlottesville
JAMA Dermatol. 2015;151(10):1117-1120. doi:10.1001/jamadermatol.2015.0976
Abstract

Importance  Nephrogenic systemic fibrosis (NSF) is a fibrosing skin disorder that develops in patients with kidney failure and has been linked to exposure to gadolinium-containing contrast agents. The time between exposure to gadolinium and the initial presentation of NSF is typically weeks to months but has been documented to be as long as 3½ years. We report a case of NSF developing 10 years after exposure to gadolinium.

Observations  A long-term hemodialysis patient was exposed to gadolinium several times between 1998 and 2004 during magnetic resonance angiography of his abdominal vessels and arteriovenous fistula. In 2014, he was seen at our clinic with new dermal papules and plaques. Biopsy of affected skin showed thickening of collagen, CD34+ spindle cells, and increased mucin in the dermis, supporting the diagnosis of NSF.

Conclusions and Relevance  The clinical history and histopathological features of this case support the diagnosis of NSF 10 years after exposure to gadolinium. Although the use of gadolinium contrast agents in patients with kidney failure has markedly decreased, patients with exposure to gadolinium years to decades previously may manifest the disease.

Introduction

Nephrogenic systemic fibrosis (NSF) was first documented in 1997 in an international registry.1 It was initially known as nephrogenic fibrosing dermatopathy because of its characteristic thickening and hardening of skin, but due to the various other organ systems that it can affect, the name was changed to NSF. The diagnosis of NSF is based on clinicopathological guidelines reported in 2011 by Girardi et al.2

The first reports of the disease correlated with the initial use of gadolinium as a contrast agent for magnetic resonance angiography in patients with renal failure.1 Approximately 380 cases of NSF have been documented in the International Nephrogenic Systemic Fibrosis Registry, with a marked increase in incidence until 2006, when the relationship between gadolinium exposure and NSF was recognized. In 2010, the US Food and Drug Administration published guidelines and black box warnings recommending avoidance of gadolinium-containing contrast agents in patients with an estimated glomerular filtration rate of less than 30 mL/min/1.73 m2 due to acute kidney injury or chronic kidney disease. The number of cases has drastically decreased since these guidelines and warnings have been established.3

Up to 95% of NSF cases have been linked to previous exposure to gadolinium-based contrast agents.1 The prevalence of NSF after exposure to gadolinium among patients receiving dialysis is 2.4%.4 Some evidence suggests that an increased number of exposures to gadolinium may increase the likelihood of developing NSF.2 After exposure to gadolinium, the longest documented time to NSF manifestation was 3½ years.5

We report a case of NSF 10 years after gadolinium exposure in a patient with chronic renal disease. To date, this is the first well-documented description of a patient who developed this disease more than a decade after exposure to gadolinium.

Report of a Case

A man in his 50s receiving chronic hemodialysis during the past 25 years for end-stage renal disease secondary to focal segmental glomerulosclerosis was seen at our clinic with recent-onset extensive papular eruption on his body and 2 new dermal plaques on his right arm. The skin lesions had first developed in June 2014, shortly after the patient had undergone fistulography using iohexol contrast. The fistulogram showed narrowing of the patient’s brachial artery–transposed basilica vein fistula but no obstruction or clot. The patient demonstrated no itching, decrease in range of motion, or hardening of the skin at that time.

Physical examination revealed a widespread eruption of dermal papules 4 to 5 mm in diameter producing linear arrays on the neck, back, chest, abdomen, and thighs without sclerosis (Figure 1). The right volar forearm had 2 indurated dermal plaques in the vicinity of the arteriovenous fistula. Microscopic examination of a punch biopsy specimen of a characteristic papule on the patient’s neck revealed thickening of dermal collagen with an increase in spindle cells and dermal mucin (Figure 2). The fibroblast-like spindle cells stained positive with a CD34 immunostain (Figure 3A), and the mucin highlighted with a colloidal iron stain (Figure 3B). Discussion with the patient and review of his medical record revealed prior exposures to gadolinium-containing contrast several times between 1998 and 2004 during magnetic resonance angiography of the abdomen, as well as several fistulograms. After 2004, the patient had received no gadolinium-containing contrast.

Figure 1.
Patient With Nephrogenic Systemic Fibrosis
Patient With Nephrogenic Systemic Fibrosis

A, Dermal papules in linear arrays on the left arm. B, Two indurated dermal plaques in the vicinity of the arteriovenous fistula (arrowheads) on the right volar forearm.

Figure 2.
Sections Stained With Hematoxylin-Eosin
Sections Stained With Hematoxylin-Eosin

A, Thickened dermal collagen containing spindle cells and interstitial mucin deposition. B, Magnification of thickened collagen with surrounding clefts containing spindle cells.

Figure 3.
CD34 Immunohistochemical Staining and Colloidal Iron–Stained Sections
CD34 Immunohistochemical Staining and Colloidal IronStained Sections

A, CD34 immunohistochemical staining that highlights the fibroblast-like spindle cells. B, Colloidal iron staining that reveals increased interstitial mucin deposition.

Discussion

Nephrogenic systemic fibrosis is included in the differential diagnosis of scleroderma-like disorders that affect the skin and internal organs. In 2007, High et al6 first reported the presence of gadolinium in skin affected by NSF as measured by electron microscopy with energy-dispersive spectroscopy. In 2010, the US Food and Drug Administration stated that 3 contrast agents (gadopentetate dimeglumine, gadodiamide, and gadoversetamide) were contraindicated in patients with acute or chronic kidney disease. Although gadolinium has been found in the skin of affected individuals, the mechanism by which fibrosis develops is unknown to date. One hypothesis proposes that infiltrating CD68+/XIIIa+ dendritic cells synthesize transforming growth factor β, a profibrotic cytokine. Another hypothesis suggests that bone marrow–derived CD45RO+/CD34+/collagen I+ circulating fibrocytes are recruited to the skin, which produce collagen and resulting fibrosis. Cowper1 found that almost all patients with NSF relate their disease onset to a recent surgical procedure or thrombotic event, suggesting that tissue or vascular injury may be an important component in the initiation of the disease.7

Nephrogenic systemic fibrosis is most common in middle-aged adults but has been described in children and the elderly. It manifests as patterned, thick, indurated plaques in a symmetric distribution on the extremities and trunk. The plaques can vary from erythematous to hypopigmented and can have an irregular, advancing edge with an amoeboid appearance. The extremities can develop joint contractures, leading to pain and loss of mobility. Patients can also be seen with yellow scleral plaques and systemic fibrosis affecting lungs, heart, and skeletal muscle.8 The differential diagnosis of NSF includes scleromyxedema, eosinophilic fasciitis, lipodermatosclerosis, scleroderma/deep morphea, eosinophilia-myalgia syndrome, and chronic graft-vs-host disease.1

The histopathology of NSF resembles scleromyxedema, with features that include thickened collagen bundles and increased dermal fibroblast-like cells that stain positive for CD34 and procollagen I. Vascular proliferation, mucin deposition, and an increased number of dendritic cells can be observed.9 However, the presence of subcutaneous involvement in NSF may be a distinguishing feature.10 In addition, patients with scleromyxedema have a distinct clinical presentation of numerous minute papules in linear arrays, often involving the face, which is spared in NSF. Due to the difficulties in distinguishing NSF and scleromyxedema on histology alone, a thorough clinical history and physical examination are necessary.

Girardi et al2 proposed clinical and histopathological criteria for NSF using data from the Yale International Nephrogenic Systemic Fibrosis Registry. Of these major clinical criteria, our patient was seen with clinical findings of patterned plaques. Of the minor clinical criteria, dermal papules, superficial plaques, and patches were present. Of the histological criteria, increased dermal cellularity, CD34+ cells with tram tracking, collagen bundles, and preserved elastic fibers were present. This led to a clinical score and a histopathological score that were consistent with NSF (Box, Table 1, and Table 2).2

Box Section Ref ID
Box.

Clinicopathological Criteria

Clinical Findings: Major Criteria
  • Patterned plaques

  • Joint contractures

  • Cobblestoning

  • Marked induration/peau d’orange

Clinical Findings: Minor Criteria
  • Puckering/linear banding

  • Superficial plaque/patch

  • Dermal papules

  • Scleral plaques (age <45 y)

Histological Findings
  • Increased dermal cellularity (score +1)

  • CD34+ cells with tram tracking (score +1)

  • Thick and thin collagen bundles (score +1)

  • Preserved elastic fibers (score −1 if absent)

  • Septal involvement (score +1)

  • Osseous metaplasia (score +3)

Table 1.  
Clinical Score
Clinical Score
Table 2.  
Histopathological Score
Histopathological Score

There have been anecdotal reports of improvement of NSF lesions after treatment with extracorporeal photopheresis, sodium thiosulfate, and pentoxifylline. Glucocorticoids, plasmapheresis, intravenous immunoglobulin, cyclophosphamide, thalidomide, intralesional interferon alpha, and topical calcipotriene therapies have had limited success. Optimization of renal function through medical therapy or transplantation appears to be effective in some cases. Physical and occupational therapy referral to maintain joint mobility is critical.11,12 Most recently, Swaminathan et al13 found that NSF-confirmed tissue expressed phosphor-70-ribosomal-S6, a protein downstream of the phosphoinositol-3-kinase and rapamycin pathways. Rapamycin is an inhibitor of phosphor-70-ribosomal-S6 directly and the 2 aforementioned pathways. Swaminathan et al reported rapid clinical resolution of NSF skin manifestations, including edema and pain in the lower extremities, with rapamycin treatment, although their results have not been duplicated to date. Avoidance of gadolinium-based contrast agents in patients with renal failure is the most effective means of preventing NSF.

Conclusions

The time course from exposure to gadolinium to the presentation of NSF was documented from weeks to 10 years in the case reported herein. All patients with symptoms of a fibrosing dermatopathy and history of kidney failure should undergo testing for NSF regardless of the number of years since last gadolinium exposure.

Back to top
Article Information

Accepted for Publication: March 20, 2015.

Corresponding Author: Krista N. Larson, BS, Department of Dermatology, University of Virginia School of Medicine, PO Box 800718, Charlottesville, VA 22908 (knl4bm@virginia.edu).

Published Online: May 27, 2015. doi:10.1001/jamadermatol.2015.0976.

Author Contributions: Ms Larson and Dr Gagnon had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Larson, Gagnon, Cropley.

Acquisition, analysis, or interpretation of data: Larson, Gagnon, Darling.

Drafting of the manuscript: Larson, Gagnon, Darling.

Critical revision of the manuscript for important intellectual content: Patterson, Cropley.

Study supervision: Cropley.

Conflict of Interest Disclosures: None reported.

References
1.
Cowper  SE. International Nephrogenic Systemic Fibrosis Registry 2001-2013.http://www.icnsfr.org. Accessed October 24, 2014.
2.
Girardi  M, Kay  J, Elston  DM, Leboit  PE, Abu-Alfa  A, Cowper  SE.  Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol. 2011;65(6):1095-1106.e7. doi:10.1016/j.jaad.2010.08.041.
PubMedArticle
3.
US Food and Drug Administration. Information on gadolinium-based contrast agents. Updated December 23, 2010. http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm142889.htm. Accessed October 24, 2014.
4.
Deo  A, Fogel  M, Cowper  SE.  Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol. 2007;2(2):264-267.
PubMedArticle
5.
Cowper  SE. Nephrogenic systemic fibrosis: history, diagnosis & the registry.http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM196233.pdf. Accessed April 4, 2015.
6.
High  WA, Ayers  RA, Cowper  SE.  Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56(4):710-712.
PubMedArticle
7.
Kucher  C, Xu  X, Pasha  T, Elenitsas  R.  Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol. 2005;32(7):484-490.
PubMedArticle
8.
Connolly  MK. Systemic sclerosis (scleroderma) and related disorders. In: Bolognia  J, Jorizzo  J, Schaffer  J, eds. Dermatology. 3rd ed. Philadelphia, PA: Elsevier/Saunders; 2012:652-654.
9.
Swartz  RD, Crofford  LJ, Phan  SH, Ike  RW, Su  LD.  Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003;114(7):563-572.
PubMedArticle
10.
Satter  EK, Metcalf  JS, Maize  JC.  Can scleromyxedema be differentiated from nephrogenic fibrosing dermatopathy by the distribution of the infiltrate? J Cutan Pathol. 2006;33(11):756-759.
PubMedArticle
11.
Weiss  AS, Lucia  MS, Teitelbaum  I.  A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. Nat Clin Pract Nephrol. 2007;3(2):111-115.
PubMedArticle
12.
Linfert  DR, Schell  JO, Fine  DM.  Treatment of nephrogenic systemic fibrosis: limited options but hope for the future. Semin Dial. 2008;21(2):155-159.
PubMedArticle
13.
Swaminathan  S, Arbiser  JL, Hiatt  KM,  et al.  Rapid improvement of nephrogenic systemic fibrosis with rapamycin therapy: possible role of phospho-70-ribosomal-S6 kinase. J Am Acad Dermatol. 2010;62(2):343-345.
PubMedArticle
×